4 Dec 2019 09:28
4 December 2019
Grant of share options and PDMR notification
Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Company"), announces that, on 1 December 2019, Nick Keher was granted share options over a total of 2,538 ordinary shares of 0.1 pence each ("Ordinary Shares"), granted under The Clinigen Group Sharesave Plan 2019. The option price for the shares is £7.09. The options are nil cost options intended to vest on 1 December 2022.
Director/PDMR | Number of share options granted | Total number of share options now held |
| Total number of ordinary shares held | Total number of ordinary shares (excluding share options) as % issued share capital |
Nick Keher | 2,538 | 136,889 |
| 3,900 | Less than 0.01% |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Nick Keher | |
2 | Reason for the notification | ||
a) | Position/status | Chief Financial Officer | |
b) | Initial notification /Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Clinigen Group plc | |
b) | Legal Entity Identifier | 213800OBIKGI2JYYS227 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 0.1 pence each
GB00B89J2419 | |
b) | Nature of the transaction | Grant of Options | |
c) | Currency | GBP | |
d) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | 2,538 | ||
| |||
e) | Aggregated information - Aggregated volume - Price - Aggregated total |
2,538 Nil
| |
f) | Date of the transaction | 1 December 2019 | |
g) | Place of the transaction | London Stock Exchange, AIM | |
-Ends-
Contact Details
Clinigen Group plc | Tel: +44 (0) 1283 495 010 |
Shaun Chilton, Group Chief Executive Officer Nick Keher, Group Chief Financial Officer Matt Parrish, Head of Investor Relations | |
Numis Securities Limited - Nominated Adviser & Joint Broker | Tel: +44 (0) 20 7260 1000 |
James Black / Freddie Barnfield |
|
| |
RBC Capital Markets - Joint Broker | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson / Elliot Thomas | |
Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
Adrian Duffield / Melanie Toyne-Sewell / Rozi Morris | Email: clinigen@instinctif.com |
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.
Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across over 100 countries, shipping approximately 6.4 million units in the year.
For more information on Clinigen, please visit www.clinigengroup.com